These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. ZNF598 co-translationally titrates poly(GR) protein implicated in the pathogenesis of C9ORF72-associated ALS/FTD. Park J; Lee J; Kim JH; Lee J; Park H; Lim C Nucleic Acids Res; 2021 Nov; 49(19):11294-11311. PubMed ID: 34551427 [TBL] [Abstract][Full Text] [Related]
13. DDX3X overexpression decreases dipeptide repeat proteins in a mouse model of C9ORF72-ALS/FTD. Fu X; Zhang Z; Hayes LR; Wright N; Asbury J; Li S; Ye Y; Sun S Exp Neurol; 2024 Jun; 376():114768. PubMed ID: 38556190 [TBL] [Abstract][Full Text] [Related]
14. UBQLN2-HSP70 axis reduces poly-Gly-Ala aggregates and alleviates behavioral defects in the C9ORF72 animal model. Zhang K; Wang A; Zhong K; Qi S; Wei C; Shu X; Tu WY; Xu W; Xia C; Xiao Y; Chen A; Bai L; Zhang J; Luo B; Wang W; Shen C Neuron; 2021 Jun; 109(12):1949-1962.e6. PubMed ID: 33991504 [TBL] [Abstract][Full Text] [Related]
15. Stable transgenic C9orf72 zebrafish model key aspects of the ALS/FTD phenotype and reveal novel pathological features. Shaw MP; Higginbottom A; McGown A; Castelli LM; James E; Hautbergue GM; Shaw PJ; Ramesh TM Acta Neuropathol Commun; 2018 Nov; 6(1):125. PubMed ID: 30454072 [TBL] [Abstract][Full Text] [Related]
16. Molecular pathology, developmental changes and synaptic dysfunction in (pre-) symptomatic human C9ORF72-ALS/FTD cerebral organoids. van der Geest AT; Jakobs CE; Ljubikj T; Huffels CFM; Cañizares Luna M; Vieira de Sá R; Adolfs Y; de Wit M; Rutten DH; Kaal M; Zwartkruis MM; Carcolé M; Groen EJN; Hol EM; Basak O; Isaacs AM; Westeneng HJ; van den Berg LH; Veldink JH; Schlegel DK; Pasterkamp RJ Acta Neuropathol Commun; 2024 Sep; 12(1):152. PubMed ID: 39289761 [TBL] [Abstract][Full Text] [Related]
17. Different CSF protein profiles in amyotrophic lateral sclerosis and frontotemporal dementia with Barschke P; Oeckl P; Steinacker P; Al Shweiki MR; Weishaupt JH; Landwehrmeyer GB; Anderl-Straub S; Weydt P; Diehl-Schmid J; Danek A; Kornhuber J; Schroeter ML; Prudlo J; Jahn H; Fassbender K; Lauer M; van der Ende EL; van Swieten JC; Volk AE; Ludolph AC; Otto M; J Neurol Neurosurg Psychiatry; 2020 May; 91(5):503-511. PubMed ID: 32132225 [TBL] [Abstract][Full Text] [Related]
18. Quality-control mechanisms targeting translationally stalled and C-terminally extended poly(GR) associated with ALS/FTD. Li S; Wu Z; Tantray I; Li Y; Chen S; Dong J; Glynn S; Vogel H; Snyder M; Lu B Proc Natl Acad Sci U S A; 2020 Oct; 117(40):25104-25115. PubMed ID: 32958650 [TBL] [Abstract][Full Text] [Related]
19. CRISPR/Cas9-mediated excision of ALS/FTD-causing hexanucleotide repeat expansion in C9ORF72 rescues major disease mechanisms in vivo and in vitro. Meijboom KE; Abdallah A; Fordham NP; Nagase H; Rodriguez T; Kraus C; Gendron TF; Krishnan G; Esanov R; Andrade NS; Rybin MJ; Ramic M; Stephens ZD; Edraki A; Blackwood MT; Kahriman A; Henninger N; Kocher JA; Benatar M; Brodsky MH; Petrucelli L; Gao FB; Sontheimer EJ; Brown RH; Zeier Z; Mueller C Nat Commun; 2022 Oct; 13(1):6286. PubMed ID: 36271076 [TBL] [Abstract][Full Text] [Related]